Zimmer Biomet Holdings Inc. acknowledged major compliance weaknesses in pre-merger Biomet's quality control processes that Zimmer only learned about after its 2015 $13bn acquisition of the firm. But the orthopedic giant said it was well into fixing the issues before US FDA investigators came knocking in the fall of 2016.
Those details came out in a 282-page response letter from Zimmer Biomet to an unfavorable, late-2016 agency inspection....






